Pipeline — registered trials by phase
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
— · Type 1 Diabetes Mellitus · Completed · est. 2014-02
Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase
— · Type 1 Diabetes Mellitus · Completed · est. 2012-08
A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)
— · Type 1 Diabetes Mellitus · Completed · est. 2014-02-27
A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects
— · Healthy · Completed
Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase
— · Rheumatoid Arthritis · Completed
Subcutaneous Rehydration Compared to Intravenous Rehydration
— · Dehydration · Completed · est. 2009-11
Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)
— · Healthy · Completed · est. 2008-01-30
Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone
— · Diabetes Mellitus · Completed · est. 2009-06
Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20
— · Diabetes Mellitus · Completed · est. 2008-02
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
— · NSCLC, Gastric Cancer · Completed · est. 2019-03-26
Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone
— · Risk Factors for or a Diagnosis of Osteoporosis · Completed · est. 2009-09-21
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20
— · Healthy Volunteers · Completed · est. 2009-08-28
Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer
— · Superficial Bladder Cancer · Completed · est. 2009-03
Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers
— · Healthy · Completed · est. 2013-11
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
— · Solid Tumor · Completed · est. 2013-10
A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase
— · Healthy · Completed
Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)
— · Type 1 Diabetes Mellitus · Completed · est. 2011-12
Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors
— · Solid Tumor · Completed · est. 2012-06
A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone
— · Healthy · Completed · est. 2010-02
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
— · Stage IV Pancreatic Cancer · Completed · est. 2014-02
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
— · Diabetes Mellitus, Type 1 · Completed · est. 2011-08
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
— · Metastatic Pancreatic Cancer · Completed · est. 2018-05-01
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
— · Diabetes Mellitus, Type II · Completed · est. 2011-08
Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis
— · Dermatitis, Allergic Contact · Completed · est. 2009-09-13
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
— · Diabetes Mellitus, Type 1 · Completed · est. 2010-02
Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
— · Bladder Cancer · Completed · est. 2009-08-11
Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)
— · Diabetes Mellitus, Type 2 · Completed · est. 2009-11
Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus
— · Type 1 Diabetes Mellitus · Completed · est. 2009-03
INFUSE Morphine Study
— · Pain · Completed · est. 2006-10
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
— · Hypogonadism, Male · Recruiting · est. 2028-03
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Halozyme is lead sponsor; 30 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-09-30Current report (material event)
- 8-K2026-09-22Current report (material event)
- 8-K2026-09-18Current report (material event)
- 8-K2026-09-16Current report (material event)
- 8-K2026-08-18Current report (material event)
- 10-Q2026-08-06Quarterly report
- 8-K2026-08-06Current report (material event)
- 8-K2026-07-02Current report (material event)
- 10-Q2026-05-11Quarterly report
- 8-K2026-05-11Current report (material event)
- 8-K2026-05-07Current report (material event)
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- 8-K2026-04-30Current report (material event)
- 8-K2026-04-24Current report (material event)
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- ARS2026-03-23Annual report to holders
- DEFA14A2026-03-23DEFA14A
- DEF 14A2026-03-23Proxy statement
- 8-K2026-03-12Current report (material event)
- 10-K2026-02-17Annual report
- 8-K2026-02-17Current report (material event)
- 8-K2026-01-28Current report (material event)
- 8-K2025-12-09Current report (material event)
- 8-K2025-12-08Current report (material event)
- 8-K2025-11-24Current report (material event)
- S-82025-11-18Employee stock plan
- 8-K2025-11-12Current report (material event)
- 8-K2025-11-07Current report (material event)
- 8-K2025-11-05Current report (material event)
- 10-Q2025-11-03Quarterly report
- 8-K2025-11-03Current report (material event)
- 8-K2025-10-14Current report (material event)
- 8-K2025-10-06Current report (material event)
- 8-K2025-10-03Current report (material event)
- 8-K2025-10-01Current report (material event)
- 10-Q2025-08-05Quarterly report
- 8-K2025-08-05Current report (material event)
- SCHEDULE 13G/A2025-07-17SCHEDULE 13G/A
- SCHEDULE 13G2025-05-13SCHEDULE 13G
- 10-Q2025-05-06Quarterly report
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.